Philips reports data showing iFR and FFR equally safe for heart disease diagnosis and treatment.

M2 EQUITYBITES-October 26, 2023-Philips reports data showing iFR and FFR equally safe for heart disease diagnosis and treatment

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) on Thursday announced the latest results demonstrating the safety of its instant wave-free ratio (iFR) in guiding percutaneous coronary intervention (PCI) for heart disease.

The study draws on patient-level data from over 42,000 individuals in the National Swedeheart Quality Registry, demonstrating that iFR and fractional flow reserve (FFR) yielded similar outcomes in terms of major adverse cardiac events (MACE). Furthermore, iFR reduces patient discomfort by up to 95.7% compared to FFR, as it avoids the use of hyperemic agents, which can have a significant impact on patient experience.

This research builds upon previous findings from the five-year outcomes of the randomised trial iFR-Swedeheart, which showed that iFR and FFR were equally safe and effective with respect to risks for MACE. The latest results from the Swedeheart registry reveal that, despite more...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT